Hartley-Asp B - Search Results

1

Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.

Kelly WK, Zhu AX, Scher H, Curley T, Fallon M, Slovin S, Schwartz L, Larson S, Tong W, Hartley-Asp B, Pellizzoni C, Rocchetti M. Kelly WK, et al. Among authors: hartley asp b. Clin Cancer Res. 2003 Jun;9(6):2098-107. Clin Cancer Res. 2003. PMID: 12796374 Clinical Trial.

2

Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.

Solit DB, Morris M, Slovin S, Curley T, Schwartz L, Larson S, Kattan MW, Hartley-Asp B, Scher HI, Kelly WK. Solit DB, et al. Among authors: hartley asp b. Cancer. 2003 Nov 1;98(9):1842-8. doi: 10.1002/cncr.11754. Cancer. 2003. PMID: 14584065 Free article. Clinical Trial.

3

Phase I clinical and pharmacologic trial of intravenous estramustine phosphate.

Hudes G, Haas N, Yeslow G, Gillon T, Gunnarsson PO, Ellman M, Nordle O, Eriksson B, Miller L, Cisar L, Kopreski M, Viaro D, Hartley-Asp B. Hudes G, et al. Among authors: hartley asp b. J Clin Oncol. 2002 Feb 15;20(4):1115-27. doi: 10.1200/JCO.2002.20.4.1115. J Clin Oncol. 2002. PMID: 11844837 Clinical Trial.

4

Differential uptake of estramustine phosphate metabolites and its correlation with the levels of estramustine binding protein in prostate tumor tissue.

Walz PH, Björk P, Gunnarsson PO, Edman K, Hartley-Asp B. Walz PH, et al. Among authors: hartley asp b. Clin Cancer Res. 1998 Sep;4(9):2079-84. Clin Cancer Res. 1998. PMID: 9748122

5

Assessment of hormone refractory prostate cancer.

Newling D, Fosså SD, Andersson L, Abrahamsson PA, Aso Y, Eisenberger MA, Khoury S, Kozlowski JS, Kelly K, Scher H, Hartley-Asp B. Newling D, et al. Among authors: hartley asp b. Urology. 1997 Apr;49(4A Suppl):46-53. doi: 10.1016/s0090-4295(99)80323-9. Urology. 1997. PMID: 9111614 Free article.

6

Estramustine depolymerizes microtubules by binding to tubulin.

Dahllöf B, Billström A, Cabral F, Hartley-Asp B. Dahllöf B, et al. Cancer Res. 1993 Oct 1;53(19):4573-81. Cancer Res. 1993. PMID: 8402630

7

Antiangiogenic effects of the quinoline-3-carboxamide linomide.

Vukanovic J, Passaniti A, Hirata T, Traystman RJ, Hartley-Asp B, Isaacs JT. Vukanovic J, et al. Cancer Res. 1993 Apr 15;53(8):1833-7. Cancer Res. 1993. PMID: 7682157

8

Evidence for a non-estrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivo.

Eklöv S, Nilsson S, Larson A, Björk P, Hartley-Asp B. Eklöv S, et al. Prostate. 1992;20(1):43-50. doi: 10.1002/pros.2990200106. Prostate. 1992. PMID: 1736276

9

The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers.

Ichikawa T, Lamb JC, Christensson PI, Hartley-Asp B, Isaacs JT. Ichikawa T, et al. Cancer Res. 1992 Jun 1;52(11):3022-8. Cancer Res. 1992. PMID: 1591718

10

Antiinvasive activity of estramustine on malignant MO4 mouse cells and on DU-145 human prostate carcinoma cells in vitro.

Mareel MM, Storme GA, Dragonetti CH, De Bruyne GK, Hartley-Asp B, Segers JL, Rabaey ML. Mareel MM, et al. Cancer Res. 1988 Apr 1;48(7):1842-9. Cancer Res. 1988. PMID: 3349462

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

71 results

Search Page

Filters